फ्लुटिकासोन और टरब्यूटालिन का इंटरैक्शन

Lung function (mean forced expiratory volume in 1 second [FEV 1 ] or morning peak expiratory flow [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids.

Acute Asthma Episodes Fluticasone Propionate DISKUS is not to be regarded as a bronchodilator and is not indicated for rapid relief of bronchospasm.

Patients should be instructed to contact their physicians immediately when episodes of asthma that are not responsive to bronchodilators occur during the course of treatment with Fluticasone Propionate DISKUS.

If bronchospasm occurs following dosing with Fluticasone Propionate DISKUS, it should be treated immediately with an inhaled, short-acting bronchodilator; Fluticasone Propionate DISKUS should be discontinued immediately; and alternative therapy should be instituted.

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids.